Dr. Putcha on the Utility of Blood-Based Assays in CRC

Article

Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.

Girish Putcha, MD, PhD, chief medical officer and clinical laboratory director, Freenome, discusses the utility of blood-based assays in colorectal cancer (CRC).

The AI EMERGE trial (NCT03688906) compared mutation detection based on circulating tumor (ct)DNA and a carcinoembryonic antigen (CEA)-based classifier and showed that a multiomic blood-based screening assay had higher sensitivity and specificity versus singular tumor-based assays in detecting early-stage colorectal cancer, says Putcha.

The sensitivity of the blood-based test was about 90% versus 47% with the ctDNA-based assay, and the specificity was 100% versus 75%, respectively. Furthermore, the sensitivity for the blood-based test was 91% compared to 31% with the CEA-based assay with a specificity of 94% for both assays. These results show that the multiomic approach holds promise for detecting disease in patients with early-stage CRC, concludes Putcha.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD